Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features

MET exon 14 (METex14) skipping is the most reported MET mutation in non-small cell lung cancer (NSCLC) and has been confirmed to respond to MET tyrosine kinase inhibitors (TKI) in clinical trials. While MET TKI tepotinib was recently approved for METex14 skipping NSCLC in China, real-world evidence...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Yan Meng, Weiping Zhou, Chenping Li, Xiangjie Zhou, Xiao Li, Liang Li, Qiye Fu, Jue Huang, Yali Yue, Xuguang Shen, Lijing Yang, Meiqing Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	tepotinib lung cancer METex14 case series MET TKI
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1383964/full